Recently, a bioinformatic analysis based on the aberrantly methylated differentially expressed genes and pathways in colorectal cancer (CRC) showed that ACTA1 may serve as an aberrant methylation‐based biomarker for precise diagnosis and treatment of CRC.36 The gene discussed is ACTA1; the disease is colorectal carcinoma.